Akebia Therapeutics (AKBA) Tops Q4 EPS by 14c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.52), $0.14 better than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• William Blair upgrades GitLab to Market Perform after strong second quarter